Pancreaticoduodenectomy (PD) with the possible addition of neoadjuvant or adjuvant therapy is the standard of care in the United States for adenocarcinoma originating in the pancreatic head, neck, and uncinate process. We reviewed 1423 patients who underwent a PD for a malignancy originating in the pancreas at our institution between 1970 and 2006. We examined 1175 PDs for ductal adenocarcinomas in greater detail. Eighteen different histological types of pancreatic cancer were identified; the most common diagnoses included ductal adenocarcinoma, neuroendocrine carcinoma, and IPMN with invasive cancer. Patients with ductal adenocarcinoma were analyzed in detail. The median age was 66 years, with patients in the present decade significantly older (68 years), on average, than patients in the three prior decades (e.g., 60 years in 1970, P=0.02). The median tumor diameter was 3 cm; 42% of the resections had positive margins and 78% had positive lymph nodes. The perioperative morbidity was 38%. The median postoperative stay declined over time, from 16 days in the 1980s to 8 days in the 2000s (P<0.001). The perioperative mortality declined from 30% in the 1970s to 1% in the 2000s (P<0.001). The median survival for all patients with ductal adenocarcinoma was 18 months (1-year survival =65 %, 2-year survival =37%, 5-year survival =18%). In a Cox proportional hazards model, pathological factors having a significant impact on survival included tumor diameter, resection margin status, lymph node status, and histologic grade. This is the largest single-institution experience with PD for pancreatic cancer. Patients who have cancers with favorable pathological features have a statistically significant improved long-term survival.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106–130.
Cancer of the Pancreas. Lifetime Risk. In: Ries LAG, Eisner MP, Kosary CL, et al., eds. SEER Cancer Statistics Review, 1975–2002, Vol. 2006. Bethesda: National Cancer Institute, 2004.
Cress RD, Yin D, Clarke L, Bold R, Holly EA. Survival among patients with adenocarcinoma of the pancreas: A population-based study (United States). Cancer Causes Control 2006;17:403–409.
Whipple AO, Parsons WB, Mullins CR. Treatment of carcinoma of the ampulla of Vater. Ann Surg 1935;102:763.
Crist DW, Cameron JL. Current status of pancreaticoduodenectomy for periampullary carcinoma. Hepatogastroenterology 1989;36:478–485.
Crist DW, Sitzmann JV, Cameron JL. Improved hospital morbidity, mortality, and survival after the Whipple procedure. Ann Surg 1987;206:358–365.
Sosa JA, Bowman HM, Gordon TA, Bass EB, Yeo CJ, Lillemoe KD, et al. Importance of hospital volume in the overall management of pancreatic cancer. Ann Surg 1998;228:429–438.
Goggins M, Lietman A, Miller RE, Yeo CJ, Jaffee E, Coleman J, et al. Use and benefits of a Web site for pancreatic cancer. JAMA 1998;280:1309–1310.
Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann JV, Hruban RH, Goodman SN, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 Patients. Ann Surg 1995;721–731; discussion 731–733.
Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, et al. Resected adenocarcinoma of the pancreas—616 Patients: Results, outcomes, and prognostic indicators. J Gastrointest Surg 2000;4:567–579.
Hruban RH, Klimstra DS, Pitman MB. Tumors of the Pancreas, 4th ed. Washington, DC: Armed Forces Institute of Pathology, 2006.
Yeo CJ, Barry MK, Sauter PK, Sostre S, Lillemoe KD, Pitt HA, Cameron JL. Erythromycin accelerates gastric emptying after pancreaticoduodenectomy. A prospective, randomized, placebo-controlled trial. Ann Surg 1993;218:229–237; discussion 237–238.
Yeo CJ, Cameron JL, Lillemoe KD, Sauter PK, Coleman J, Sohn TA, et al. Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial. Ann Surg 2000;232:419–429.
Yeo CJ, Cameron JL, Maher MM, Sauter PK, Zahurak KL, Talamini MA, et al. A prospective randomized trial of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy. Ann Surg 1995;222:580–588; discussion 588–592.
Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Talamini MA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: Pathology, complications, and outcomes. Ann Surg 1997;226:248–257; discussion 257–260.
Riall TS, Cameron JL, Lillemoe KD, Campbell KA, Sauter PK, Coleman J, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for perimpullary adenocarcinoma—Part 3: Update on 5-year survival. J Gastrointest Surg 2005;9:1191–1204; discussion 1204–1206.
Greene FL, Page DL, Fleming ID, Frtiz AG, Balch CM, Haller DG, Morrow M. AJCC Cancer Staging Manual. Exocrine Pancreas, 6th ed. New York: Springer, 2002.
Busnardo AC, DiDio LJ, Tidrick RT, Thomford NR. History of the pancreas. Am J Surg 1983;146:539–550.
Andren-Sandberg A, Wagner M, Tihanyi T, Lofgren P, Friess H. Technical aspects of left-sided pancreatic resection for cancer. Dig Surg 1999;16:305–312.
Whipple AO. The rationale of radical surgery for cancer of the pancreas and ampullary region. Ann Surg 1941;114:612–615.
Halsted W. Contributions to the surgery of the bile passages, especially of the common bile-duct. Boston Medical and Surgical Journal 1899;141.
Howard JM. Development and progress in resective surgery for pancreatic cancer. World J Surg 1999;23:901–906.
Whipple AO. Surgical treatment of carcinoma of the ampullary region and head of the pancreas. Am J Surg 1938;40:260–263.
Cooperman AM, Herter FP, Marboe CA, Helmreich ZV, Perzin KH. Pancreatoduodenal resection and total pancreatectomy—An Institutional review. Surgery 1981;90:707–712.
Herter FP, Cooperman AM, Ahlborn TN, Antinori C. Surgical experience with pancreatic and periampullary cancer. Ann Surg 1982;195:274–281.
Nakase A, Matusmoto Y, Uchida K, Honjo I. Surgical treatment of cancer of the pancreas and the periampullary region: Cumulative results in 57 institutions in Japan. Ann Surg 1977;185:52–57.
Smith R. Progress in the surgical treatment of pancreatic disease. Am J Surg 1973;125:143–153.
Tepper J, Nardi G, Sutt H. Carcinoma of the pancreas: Review of MGH experience from 1963 to 1973. Analysis of surgical failure and implications for radiation therapy. Cancer 1976;37:1519–1524.
Warren KW, Choe DS, Plaza J, Relihan M. Results of radical resection for periampullary cancer. Ann Surg 1975;181:534–540.
Clancy TE, Ashley SW. Pancreaticoduodenectomy (Whipple operation). Surg Oncol Clin N Am 2005;14:533–552, vii.
Fernandez-del Castillo C, Rattner DW, Warshaw AL. Standards for pancreatic resection in the 1990s. Arch Srug 1995;130:295–299; discussion 299–300.
Warren KW, Braasch JW, Thum CW. Carcinoma of the pancreas. Surg Clin North Am 1968;48:601–618.
Fish JC, Cleveland BR. Pancreaticoduodenectomy for periampullary carcinoma. Analysis of 38 Cases. Ann Surg 1964;159:469–476.
Monge JJ, Judd ES, Gage RP. Radical pancreatoduodenectomy: A 22-year experience with the complications, mortality rate, and survival rate. Ann Surg 1964;160:711–722.
Morris PJ, Nardi GL. Pancreaticoduodenal cancer. Experience from 1951 to 1960 with a look ahead and behind. Arch Surg 1966;92:834–837.
Warren KW, Kune GA. Surgical approach to jaundice. Hosp Med 1966;2:46–55.
Trede M, Schwall G, Saeger HD. Survival after pancreatoduodenectomy. 118 Consecutive resections without an operative mortality. Ann Surg 1990;211:447–458.
Makary MA, Winter JM, Cameron JL, Campbell KA, Chang D, Cunningham SC, et al. Pancreaticoduodenectomy in the very elderly. J Gastrointest Surg 2006;10:347–356.
Saleh MM, Norregaard P, Jorgensen HL, Andersen PK, Matzen P. Preoperative endoscopic stent placement before pancreaticoduodenectomy: A meta-analysis of the effect on morbidity and mortality. Gastrointest Endosc 2002;56:529–534.
Takada T, Yasuda H, Amano H, Yoshida M, Uchida T. Simultaneous hepatic resection with pancreato-duodenectomy for metastatic pancreatic head carcinoma: Does it improve survival? Hepatogastroenterology 1997;44:567–573.
A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med 2004;350:2050–2059.
Finlayson SR, Laycock WS, Birkmeyer JD. National trends in utilization and outcomes of antireflux surgery. Surg Endosc 2003;17:864–867.
Richter A, Niedergethmann M, Sturm JW, Lorenz D, Post S, Trede M. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-Year experience. World J Surg 2003;27:324–329.
Wenger FA, Peter F, Zieren J, Steiert A, Jacobi CA, Muller JM. Prognosis factors in carcinoma of the head of the pancreas. Dig Surg 2000;17:29–35.
Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999;230:776–782; discussion 782–784.
Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200–1210.
Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899–903.
Yeo CJ, Abrams RA, Grochow LB, Sohn TA, Ord SE, Hruban RH, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: Postoperative adjuvant chemoradiation improves survival. A prospective, signle-institution experience. Ann Surg 1997;225:621–633; discussion 633–636.
Radiation Therapy Oncology Group. ROG 97-04. Available at: http://rtog.org/members/protocols/97-04/97-04.pdf.
Nukui Y, Picozzi VJ, Traverso LW. Interferon-based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 2000;179:367–371.
Crance CH, Ellis LM, Abbruzzese JL, Amos C, Xiong HQ, Ho L, et al. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 2006;24:1145–1151.
Jaffee EM, Hruban RH, Biedrzycki B, Laheru D, Schepers K, Sauter PR, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: A phase I trial of safety and immune activation. J Clin Oncol 2001;19:145–156.
Winter JM, Cameron JL, Lillemoe KD, Campbell KA, Chang D, Riall TS, et al. Periampullary and pancreatic incidentaloma: A single institution’s experience with an increasingly common diagnosis. Ann Surg 2006;243:673–683.
Rights and permissions
About this article
Cite this article
Winter, J.M., Cameron, J.L., Campbell, K.A. et al. 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg 10, 1199–1211 (2006). https://doi.org/10.1016/j.gassur.2006.08.018
- pancreatic cancer
- ductal adenocarcinoma